Trial: 202001157

A MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, EFFICACY,TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF,OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY
B-CELL NON-HODGKIN’S LYMPHOMA

Phase

I

Principal Investigator

Bartlett, Nancy

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov